Zollinger-Ellison Syndrome (Gastrinoma)-Global API Manufacturers, Marketed and Phase III Drugs Landscape, 2016

Press Release   •   May 26, 2016 13:07 EDT

Zollinger-Ellison Syndrome (Gastrinoma)-Global API Manufacturers, Marketed and Phase III Drugs Landscape, 2016”, provides comprehensive insights about the marketed drugs, drug sales, Phase III pipeline drugs and their API Manufacturers across the globe.

A key objective of the Zollinger-Ellison Syndrome (Gastrinoma) Report is to understand the market and pipeline status of the drugs around the Zollinger-Ellison Syndrome (Gastrinoma) to explore the generic development opportunities, licensing opportunities and to gain competitive advantage on designing pipeline strategies. The Zollinger-Ellison Syndrome (Gastrinoma) Report provides the historical and forecasted sales of the drugs till 2018.

The Report gives insights into patents providing the patent protection data and marketing exclusivity of all the drugs across the Zollinger-Ellison Syndrome (Gastrinoma).

While the leading brands, companies and chemicals are considered thoroughly, the report also provides details on the Global API Manufacturers across the globe covering Drug Master Filings of US, Europe and API Manufacturers in Asia specifically China and India.

Please note: This report requires certain updates. We have all the information available but require 3 business days to complete the process and ensure it is as up-to-date as possible. Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Check complete report @

Scope of Report:

  • A snapshot of the global Market and Phase III therapeutics scenario for Zollinger-Ellison Syndrome (Gastrinoma).
  • A review of the marketed products under prescription for Zollinger-Ellison Syndrome (Gastrinoma), regulatory information and marketing status.
  • Coverage of global patent coverage and detailed commentaries on the US patent challenges.
  • Graphical representation of investigational products for patent expiry and market exclusivities across the globe.
  • Product profiles for marketed products for Zollinger-Ellison Syndrome (Gastrinoma) with complete description of mechanism of action, therapeutic class, target, route(s) of administration and chemical details.
  • Coverage of API Manufacturers for Zollinger-Ellison Syndrome (Gastrinoma) drugs in the United States, Europe and Asian Regions with location details.
  • Coverage of Regulatory filings in the US, Europe, and Asia specifically India and China for Zollinger-Ellison Syndrome (Gastrinoma) drugs.
  • Coverage of Route of Synthesis of Active Pharmaceutical Ingredient associated with Zollinger-Ellison Syndrome (Gastrinoma) drugs.
  • Coverage of Zollinger-Ellison Syndrome (Gastrinoma) Phase III pipeline products featuring sections on product description, mechanism of action, Chemical details and research & development progress.
  • Coverage of the United States Drug Master File (US DMF) available for Phase III Pipeline Drugs.
  • Key discontinued Marketed products.
  • Global Sales Figure to 2018.
  • Get Sample Brochure of the report @

    Reasons to buy:

  • Evaluate the marketing status and exclusivity details of Zollinger-Ellison Syndrome (Gastrinoma) key products to exploit opportunities for generic drug development opportunities.
  • Identify and understand important and diverse types of therapeutics under Phase III development for Zollinger-Ellison Syndrome (Gastrinoma).
  • Design effective counter-strategies to gain competitive advantage by identifying the key patent expiry details and exclusivity with respect to Zollinger-Ellison Syndrome (Gastrinoma).
  • API intelligence over marketed drugs for Zollinger-Ellison Syndrome (Gastrinoma)and gaining primary intelligence over active ingredients manufacturers across the globe.
  • API intelligence over leading Phase III Pipeline drugs.
  • Develop and design strategies by identifying the API manufacturers for Phase III Pipeline products to enhance and expand business potential and scope.
  • Understanding the scope of the Phase III Drugs with nil regulatory filings.
  • Understanding the chemical route of synthesis of approved drugs for Zollinger-Ellison Syndrome (Gastrinoma).
  • Uncovering opportunities in the rapidly growing US market.
  • Order a copy of Zollinger-Ellison Syndrome (Gastrinoma) report @

    MarketIntelReports (MIR) aim to empower our clients to successfully manage and outperform in their business decisions, we do this by providing Premium Market Intelligence, Strategic Insights and Databases from a range of Global Publishers.

    A group of industry veterans who are well experienced in reputed international consulting firms after identifying the sourcing needs of MNCs for market intelligence, have together started this business savior MarketIntelReports.

    MIR intends to be a one-stop shop with an intuitive design, exhaustive database, expert assistance, secure cart checkout and data privacy integrated. It curates the list of reports, publishers and studies to ensure that the database is constantly updated to dynamically meet the targeted, specific needs of our clients.

    MarketIntelReports currently has more than 10,000 plus titles and 35+ publishers on our platform and growing consistently to fill the “Global Intelligence Demand – Supply Gap”. We cover more than 15 industry verticals being: Automotive, Electronics, Manufacturing, Pharmaceuticals, Healthcare, Chemicals, Building & Construction, Agriculture, Food & Beverages, Banking & Finance, Media and Government, Public Sector Studies.

    Contact us:

    Sales Manager
    Mayur S.

    2711 Centerville Road, Suite 400,
    United States
    Telephone: 1-302-684-6088